Liver International

• Efficacy and Safety of DAAs for Hepatitis C in the Elderly This review assessed and compared the efficacy and safety of DAA therapy among the elderly and younger patients with chronic HCV infection. Are results comparable?
  Liver International, October 2019
• Metabolically Healthy Obesity and Fibrosis Progression in NAFLD Do obese individuals with NAFLD who are "metabolically healthy" (i.e., without diabetes, hypertension or high lipid levels) differ in fibrosis progression versus those with these risk factors?
  Liver International, October 2019
• NAFLD, Liver Fibrosis Score and Cognitive Function in Adults Is there an association between liver fibrosis, even prior to its clinical manifestation, and impairment in cognitive function in older adults?
  Liver International, October 2019
• NASH and Risk of Advanced Colorectal Neoplasm This study indicates that the histological severity of NAFLD is strongly associated with advanced colorectal neoplasm.
  Liver International, October 2019
• Disparities in Uptake of DAA Therapy for HCV Among PWID This study examined socioeconomic and demographic disparities in access to and initiation of direct-acting antiviral treatment among HCV-positive people who inject drugs.
  Liver International, September 2019
• Prevalence of CAM Modalities in Patients With Chronic HBV How prevalent is the use of complementary and alternative medicine therapies in patients with chronic hepatitis B? What treatments are most commonly used and how safe are they?
  Liver International, August 2019
• Cardiovascular Morbidity and Mortality Post-liver Transplant This study found that liver transplant patients are at high risk of developing cardiovascular events post transplantation, even with no pre-existing risk factors. Can predictors be determined?
  Liver International, August 2019
• CAD and Cardiovascular Events After Liver Transplantation Is the risk of cardiovascular events during the immediate period after liver transplant associated with the presence or severity of pre-existing coronary artery disease?
  Liver International, August 2019
• Prescription of Statins in Suspected NAFLD and High CVD Risk Might most patients with suspected non-alcoholic fatty liver disease benefit from statin therapy?
  Liver International, August 2019
• HCV Infection and Non-Hepatic Malignancies in the DAA Era What are the effects of HCV viral eradication on non-hepatic cancers? This review focused on the impact of DAA therapy on non-Hodgkins' lymphoma and extrahepatic solid tumors.
  Liver International, July 2019
• HCC in Patients With NAFLD Without Cirrhosis This study compared the clinical characteristics of patients with non-cirrhotic NAFLD-HCC to those with cirrhosis. Do outcomes differ between the two groups?
  Liver International, July 2019
• Autoimmune Hepatitis: Current and Future Therapeutic Options This review summarizes current as well as promising investigational options for autoimmune hepatitis, a rare immune-mediated liver disease.
  Liver International, July 2019
• Treatment With DAAs for HCV and Risk of HCC This study indicates that the risk of hepatocellular carcinoma remains high in HCV patients with advanced fibrosis, even after achieving viral eradication with DAAs.
  Liver International, June 2019
• SVR and Long-term Glycemic Control in Patients With T2DM+HCV Successful HCV treatment among patients with type 2 diabetes significantly reduces HbA1c shortly after treatment. Are these reductions sustained over time?
  Liver International, June 2019
• Outcomes in HBV-related Acute on Chronic Liver Failure This study compared the 5-year survival rate and incidence rate of hepatocellular carcinoma between patients with HBV-related acute on chronic liver failure and HBV cirrhosis.
  Liver International, June 2019
• HCV Late Relapse in Patients With DAA-related SVR at Week 12 What are the clinical, epidemiological and virological features of patients who experience late relapse after successful treatment with direct-acting antivirals?
  Liver International, June 2019
• Drug-induced Liver Injury With Skin Reactions This review explores factors causing concomitant drug-induced skin and liver injury. What are the characteristics of liver involvement in patients with severe cutaneous adverse reaction?
  Liver International, May 2019
• AF: Highly Prevalent Yet Undertreated in Patients With NASH This study found that the prevalence of atrial fibrillation in patients with NASH is twice that of the general population. Are these patients receiving appropriate anticoagulation therapy?
  Liver International, May 2019
• When Is Stopping Immunosuppressives in AIH Justified How long should immunosuppressive treatment of autoimmune hepatitis be continued, and which patients are suitable for drug withdrawal?
  Liver International, May 2019
• Parental NAFLD Increases Risk of NAFLD in Offspring Are individuals with a parental history of hepatic steatosis at increased risk for NAFLD?
  Liver International, May 2019